GlassScriptPhysician profile
Sanjay K Bhendwal
NPI 1770519944
$12,195.64
in general payments reported to CMS, 2019-2025
55 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $1,737 · 2021: $2,085 · 2022: $1,814 · 2023: $1,755 · 2024: $1,619 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,000.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,435.10 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,092.70 | 2019-2025 | |
| Novo Nordisk INC | $949.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $844.69 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $490.38 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $382.45 | 2019-2023 | Verquvo, Lagevrio |
| Glaxosmithkline, LLC. | $375.68 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $374.27 | 2020-2023 | Xarelto |
| Abbott Laboratories | $332.44 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $314.32 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $290.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.95 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $232.38 | 2020-2022 | |
| Daiichi Sankyo INC. | $229.11 | 2019-2023 | Injectafer |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Bhendwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.